Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Durvalumab (IMFINZI) plus fractionated radiotherapy in resectable head and neck squamous cell carcinoma
2019-001641-40Phase 2Terminated
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- May 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoints: Immunobiomarker modulation, Local and regional clinical-radiological activity before surgery and 1 more. Started May 2021; status: terminated.
02
Drugs
durvalumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2019-001641-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001641-40.